Please assess the completion status of the following clinical trial:

Trial Title: Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients, 18 years of age or older, with Hodgkin's lymphoma, Non-Hodgkin lymphoma (NHL), multiple myeloma (MM), or chronic lymphocytic leukemia (CLL) are eligible.~* Patients must have a life expectancy of at least 12 weeks.~* Patients must have a Zubrod performance status of 0-2.~* Patients must sign an informed consent.~* Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of \> 1,000 or cells/mm3 and platelet count \>50,000/mm3 and absence of a regular red blood cell or platelet transfusion requirement.~* Patients should have adequate hepatic function with a total bilirubin \< 2 mg/dl and SGOT or SGPT \< two times the upper limit of normal, and adequate renal function as defined by a serum creatinine \< 2.0 x upper limit of normal.~* Patients must have received at least two previous chemotherapy regimens for their disease.~* Patients must have measurable disease (NHL) or evaluable disease (MM, CLL).~Exclusion Criteria:~* Patients with symptomatic brain metastases are excluded from this study.~* Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception.~* Patients may receive no other concurrent chemotherapy or radiation therapy during this trial.~* Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 Combination Treatment (Type: EXPERIMENTAL): Treatment with combination therapy as follows:~VP-16 at 50 mg/day, orally for 14 days every 28 days; Chlorambucil at 0.1 mg/kg/day orally for 14 days every 28 days; Vincristine at 2 mg intravenously every 14 days; Dexamethasone at 200 mg intravenously every 24 days; Rituxan (rituximab) at 375 mg/m2 intravenously every 14 day; Levofloxacin at 500 mg orally daily; Diflucan at 200 mg orally daily~At least 2 courses, but no more than 8 courses total, will be administered to each patient

Based on this trial design, predict the completion outcome and termination type (if applicable).